openPR Logo
Press release

Alzheimer’s Disease Therapeutics Market Forecast – (2016-2020)

06-08-2016 09:00 AM CET | Health & Medicine

Press release from: MarketIntelReports

Alzheimer’s Disease Therapeutics Market Forecast –

Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

Summary of the report:
Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.

Check Complete Report @ http://www.marketintelreports.com/report/gbihc399mr/alzheimers-disease-therapeutics-in-major-developed-markets-to-2021--aging-population-and-improved-disease-understanding-increase-demand-for-disease-modifying-agents

The AD market has a lack of therapeutic options.
• Which classes of drug dominate the market?
• What newly approved therapies have entered the market?
• How do the leading marketed therapies compare clinically?
• How will the new therapies be positioned in the treatment of AD?
• How have selected late-stage pipeline therapies performed in clinical trials?
• The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
• Which molecular targets appear most frequently in the pipeline?
• AD clinical trials have an overall attrition rate of 94%.
• What are the failure rates for individual Phases of clinical development?
• How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
• The AD market is forecast to rise from a value of $5.2 billion in 2014 to $11.3 billion in 2021, at a CAGR of 11.8% across the eight major markets assessed.
• How much of a role will disease prevalence and new product approvals play in market growth?
• Will generic competition have a significant impact on the market over the forecast period?
• There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.
• Which territories show the most deal activity?
• What were the trends in deal completion by product stage of development?
• What were the conditions of the key licensing or co-development deals to take place in AD?

This report will allow you to
• Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
• Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
• Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
• Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
• Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Download Sample Brochure of Report @ http://www.marketintelreports.com/pdfdownload.php?id=gbihc399mr

***Early Buyers will receive 20% discount on report, this is valid till 30th June 2016

About us:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

Contact us:
Sales Manager
Mayur S
www.marketintelreports.com
sales@marketintelreports.com
Telephone: 1-302-684-6088

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer’s Disease Therapeutics Market Forecast – (2016-2020) here

News-ID: 343715 • Views:

More Releases from MarketIntelReports

Study on Future Growth Drivers of the Cloud Integration Market
Cloud Integration or integration platform as a service (iPaaS) is one of the fast emerging forms of cloud computing services that are delivered to configure data with various application programs. These application programs range from enterprise risk management (ERM), customer relationship management (CRM), database management system (DBMS), and business process management to web conferencing, and emails, etc. Cloud integration services are especially designed to help organizations of all sizes to
Analysis of Variables Pushing the Expansion of the Workforce Management Market
Workforce Management is an integrated set of processes that an institution or organization uses to optimize the productivity of its employees on the individual, departmental, and entity-wide levels. This report identifies the Workforce Management market size in terms of value for the year 2014-2016, and forecast of the same for year 2021. It highlights potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges,
Study on Future Growth Drivers of the Blockchain Market
The blockchain technology market size is estimated to grow from USD 210.2 Million in 2016 to USD 2,312.5 Million by 2021, at a Compound Annual Growth Rate (CAGR) of 61.5% during the forecast period. In the report, 2015 is considered the base year, while the forecast period is 2016–2021. The objective of the report is to define, describe, and forecast the blockchain technology market on the basis of providers, applications, deployment
Glass Bonding Adhesives Market by End-Use Industry (Furniture, Electronics, Medi …
The use of adhesives and glues as a bonding agent between glass and other materials is increasing now a days. The glass bonding adhesives has a wide range of applications in automotive industry for bonding the glass in vehicles, manufacturing of water tanks and optical glasses, bonding of window glass to frame or structure etc. The selection of a suitable adhesive for proper bonding of glass depends upon various factors

All 4 Releases


More Releases for Disease

Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and